{"entity":{"id":"venetoclax-plus-obinutuzumab","kind":"pairing","name":"Venetoclax + obinutuzumab (12 months)","aka":[],"tldr":"Venetoclax plus obinutuzumab, one year of a pill plus an antibody, was the first fixed-duration, chemotherapy-free CLL regimen, with half of patients still in remission at six years.","summary":"This combination gives one year of venetoclax, a BCL-2 inhibitor, with the CD20 antibody obinutuzumab in chronic lymphocytic leukaemia; it was the first fixed-duration, chemotherapy-free regimen for the disease. Obinutuzumab debulks the leukaemia and reduces the risk of tumour lysis syndrome before venetoclax is ramped up, and adds antibody-dependent cellular cytotoxicity, while venetoclax clears measurable residual disease. The evidence is two positive phase 3 trials: CLL14 in unfit patients, where a large share remain in remission at long follow-up, and CLL13 (GAIA) in fit patients, where obinutuzumab outperformed rituximab as the venetoclax partner and adding ibrutinib deepened the effect further. The regimen is described in the CLL14 paper.","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT02242942: CLL14","url":"https://clinicaltrials.gov/study/NCT02242942"},{"label":"ClinicalTrials.gov NCT02950051: CLL13 / GAIA","url":"https://clinicaltrials.gov/study/NCT02950051"}],"tags":[],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":["bcl2","cd20"],"drugs":["venetoclax","obinutuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cll14","cll13-gaia"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"a":"venetoclax","b":"obinutuzumab","rationale":"Obinutuzumab debulks and reduces TLS risk before venetoclax ramp-up and adds ADCC-mediated killing; venetoclax clears MRD.","evidence":"Two positive phase 3 trials.","pairingType":"combination"},"route":"/pairings/venetoclax-plus-obinutuzumab/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"drug":[{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"trial":[{"id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/"},{"id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/"}],"paper":[{"id":"paper-cll14-venetoclax-obinutuzumab-nejm-2019","kind":"paper","name":"CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients","route":"/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/"}]}}